Project Grant R01AR083994
- The University of Michigan received a $1,540,008 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on June 5, 2025. The grant, titled "Integrated Program for Cutaneous Immune-Stromal Interactions in SLE (IPCISS)", aims to develop knowledge about the pathogenesis and triggers of cutaneous lupus erythematosus (CLE) in systemic lupus erythematosus (SLE) patients to facilitate novel treatment...
- This $172,584 five-year Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846) aims to prioritize genes potentially causal to the development of systemic sclerosis (SSc) using multi-omics analyses. The research will leverage the candidate's expertise in genetic epidemiology and computational biology to broaden their skills in multi-omics analysis...
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
- This $1,622,775 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the critical role of mitochondrial oxidative metabolism in determining muscle stem cell fate and function. The Van Andel Research Institute, a non-profit biomedical research organization in Grand Rapids, Michigan, will conduct this research over a 3-year period...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), awarded a $200,156 Project Grant to the Regents of the University of Minnesota. This 5-year grant, with an ultimate completion date of Jul 31, 2030, will fund an Interdisciplinary Musculoskeletal Research Training Program. The program aims to provide comprehensive, multi-level training to 5 predoctoral students...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $726,898 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Weill Medical College of Cornell University. The award aims to conduct personalized immunomonitoring research to improve understanding of the autoimmune disease juvenile dermatomyositis (JDM). The project will utilize single-cell transcriptional profiling of patient blood samples to identify...
- This federal Project Grant award of $113,090 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research by Dr. Mengqi Huang at the University of Pittsburgh to investigate the epigenetic regulatory networks driving increased expression of TGF-β3 in systemic sclerosis (scleroderma) skin myofibroblasts. The central objective is to advance knowledge on the regulation of...
- This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...
- This $366,639 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to understand the mechanisms driving poor outcomes in women with dermatomyositis (DM), a rare autoimmune disease. The project aims to establish the Southern California Dermatomyositis Disease Network (SCAD) to recruit diverse DM patients and investigate whether...
- This $216,113 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to characterize impairment of hematopoietic stem cells (HSCs) and their role in the hematological abnormalities associated with systemic autoimmune diseases like systemic lupus erythematosus (SLE). The research aims to elucidate the cell-extrinsic factors and epigenetic...
The University of Michigan received a $637,567 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant will fund research to investigate the role of the A20 protein and the DREAM transcriptional repressor in adipogenesis and systemic sclerosis, a fibrotic autoimmune disease. The research aims to better understand the mechanisms driving the loss of dermal white adipose tissue and the transformation of resident cells into activated myofibroblasts, which contribute to tissue fibrosis in systemic sclerosis. The project will use single-cell RNA sequencing analysis to identify key genes and pathways involved in these processes, with the goal of developing novel therapeutic strategies to limit adverse tissue remodeling in systemic sclerosis and other fibrotic diseases. The award period extends from September 2025 to August 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $637.6k | 9/17/25 |